

Seth M Steinberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6357994/publications.pdf>

Version: 2024-02-01

286
papers

14,293
citations

28274

55
h-index

25787

108
g-index

286
all docs

286
docs citations

286
times ranked

17664
citing authors

#	ARTICLE	IF	CITATIONS
1	Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells. Blood Advances, 2023, 7, 575-585.	5.2	52
2	Donor source and post-transplantation cyclophosphamide influence outcome in allogeneic stem cell transplantation for GATA2 deficiency. British Journal of Haematology, 2022, 196, 169-178.	2.5	18
3	Factors Impacting Overall and Event-Free Survival following Post-Chimeric Antigen Receptor T Cell Consolidative Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 31.e1-31.e9.	1.2	8
4	Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL. Journal of Clinical Oncology, 2022, 40, 932-944.	1.6	93
5	Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy. Clinical Cancer Research, 2022, 28, 1353-1362.	7.0	10
6	A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma. Oncologist, 2022, 27, e273-e285.	3.7	22
7	A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer. Oncologist, 2022, 27, 198-209.	3.7	18
8	Prospective phase II trial of montelukast to treat bronchiolitis obliterans syndrome after hematopoietic cell transplant and investigation into BOS pathogenesis. Transplantation and Cellular Therapy, 2022, , .	1.2	5
9	Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma. Blood Advances, 2022, 6, 2667-2680.	5.2	17
10	Safety, Activity, and Long-term Outcomes of Pomalidomide in the Treatment of Kaposi Sarcoma among Individuals with or without HIV Infection. Clinical Cancer Research, 2022, 28, 840-850.	7.0	20
11	The association of FDG PET/CT and NaF PET/CT with survival outcomes in patients (pts) with metastatic genitourinary malignancies (mGU) treated with cabozantinib + nivolumab +/- ipilimumab (CaboNivo +/-) Tj ETQq1 1106784314rgBT /O		
12	Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity. Neuro-Oncology, 2022, 24, 1978-1988.	1.2	14
13	A phase II trial of the super-enhancer inhibitor Minnelideâ„¢ in advanced refractory adenosquamous carcinoma of the pancreas. Future Oncology, 2022, 18, 2475-2481.	2.4	13
14	Extended progression-free survival and long-term safety of nirogacestat in patients with desmoid tumors.. Journal of Clinical Oncology, 2022, 40, 11545-11545.	1.6	3
15	Durvalumab (D) in combination with olaparib (O) for advanced, previously treated non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2022, 40, e21153-e21153.	1.6	1
16	Targeting genomic instability in extrapulmonary small cell neuroendocrine cancers: A phase II study with ATR inhibitor berzosertib and topotecan.. Journal of Clinical Oncology, 2022, 40, 8518-8518.	1.6	0
17	Results of a phase I trial of ganitumab plus dasatinib in patients with rhabdomyosarcoma (RMS).. Journal of Clinical Oncology, 2022, 40, 11561-11561.	1.6	2
18	Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer. Clinical Cancer Research, 2021, 27, 1391-1398.	7.0	20

#	ARTICLE	IF	CITATIONS
19	Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma. <i>Investigational New Drugs</i> , 2021, 39, 821-828.	2.6	24
20	Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair-targeted therapies. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	35
21	Predictors of hematologic malignancy relapse in patients with advanced chronic graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2021, 56, 1584-1592.	2.4	0
22	Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma. <i>Oncologist</i> , 2021, 26, e847-e858.	3.7	31
23	Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases. <i>Blood Advances</i> , 2021, 5, 1660-1670.	5.2	35
24	Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma. <i>Oncologist</i> , 2021, 26, 288-e541.	3.7	10
25	Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. <i>Cancer Cell</i> , 2021, 39, 566-579.e7.	16.8	107
26	First-in-human phase I/II trial of PRGN-2009 vaccine as monotherapy or with bintrafusp alfa in patients with recurrent/metastatic (R/M) human papillomavirus (HPV)-associated cancers (HPVC) and as neoadjuvant/induction therapy in locoregionally advanced (LA) HPV oropharyngeal (OP) and sinonasal (SN) squamous cell cancer (SCC). <i>Journal of Clinical Oncology</i> , 2021, 39, TPS6092-TPS6092.	1.6	2
27	Clinical Indicators for Long-Term Survival with Immune Checkpoint Therapy in Advanced Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 507-512.	3.7	8
28	Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL. <i>Journal of Clinical Oncology</i> , 2021, 39, 1650-1659.	1.6	173
29	Clinical value of 18FDG PET/MRI in muscle-invasive, locally advanced, and metastatic bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 787.e17-787.e21.	1.6	16
30	Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma. <i>Cancers</i> , 2021, 13, 3342.	3.7	14
31	Subsequent Cancers in Patients Affected with Moderate or Severe Chronic Graft-versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 937.e1-937.e7.	1.2	5
32	Clinical characterization and cytokine profile of fatigue in hematologic malignancy patients with chronic graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2021, 56, 2934-2939.	2.4	4
33	Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma. <i>JAMA Oncology</i> , 2021, 7, 1678.	7.1	12
34	Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells. <i>Blood</i> , 2021, 138, 2469-2484.	1.4	79
35	Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100231.	1.1	16
36	Characterization of Outcomes by Surgical Management of Lung Neuroendocrine Tumors Associated With Cushing Syndrome. <i>JAMA Network Open</i> , 2021, 4, e2124739.	5.9	5

#	ARTICLE	IF	CITATIONS
37	Tolerability of Coronavirus Disease 2019 Vaccines, BNT162b2 and mRNA-1273, in Patients With Thymic Epithelial Tumors. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100229.	1.1	7
38	Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days. <i>Blood Advances</i> , 2021, 5, 5312-5322.	5.2	24
39	Characteristics of Matriculants to Thoracic Surgery Residency Training Programs. <i>Annals of Thoracic Surgery</i> , 2021, 112, 2070-2075.	1.3	12
40	Phase 2 Study of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas. <i>Blood</i> , 2021, 138, 4504-4504.	1.4	3
41	<i>Phase I/II Study of Reduced Dosing of Post-Transplantation Cyclophosphamide (PTCy) after HLA-Haploidentical Bone Marrow Transplantation</i>. <i>Blood</i> , 2021, 138, 101-101.	1.4	14
42	Reply to K. Takada etÂal.. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100250.	1.1	0
43	Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy. <i>Frontiers in Oncology</i> , 2021, 11, 789078.	2.8	6
44	Prospective Study of a Novel, Radiation-Free, Reduced-Intensity Bone Marrow Transplantation Platform for Primary Immunodeficiency Diseases. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 94-106.	2.0	28
45	A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer. <i>Oncologist</i> , 2020, 25, 479-e899.	3.7	39
46	Stage and disease-free interval help select patients for surgical management of locally recurrent and metastatic adrenocortical carcinoma. <i>Journal of Surgical Oncology</i> , 2020, 121, 228-233.	1.7	2
47	Qualities and characteristics of applicants associated with successful matriculation to pediatric surgery fellowship training. <i>Journal of Pediatric Surgery</i> , 2020, 55, 2075-2079.	1.6	12
48	Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment. <i>Gynecologic Oncology</i> , 2020, 159, 88-94.	1.4	16
49	Phase 1 study of the immunotoxin LMBâ€100 in patients with mesothelioma and other solid tumors expressing mesothelin. <i>Cancer</i> , 2020, 126, 4936-4947.	4.1	31
50	Pediatric PK/PD Phase I Trial of Pexidartinib in Relapsed and Refractory Leukemias and Solid Tumors Including Neurofibromatosis Type Iâ€Related Plexiform Neurofibromas. <i>Clinical Cancer Research</i> , 2020, 26, 6112-6121.	7.0	13
51	Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 3672-3684.	1.6	78
52	Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study. <i>Clinical Cancer Research</i> , 2020, 26, 4268-4279.	7.0	126
53	Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung. <i>Sarcoma</i> , 2020, 2020, 1-6.	1.3	17
54	Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 2519-2529.	1.6	93

#	ARTICLE	IF	CITATIONS
55	Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases. <i>Future Oncology</i> , 2020, 16, 899-909.	2.4	22
56	Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 258-267.e1.	1.9	11
57	Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus-associated multicentric Castlemans disease. <i>Blood</i> , 2020, 135, 2316-2319.	1.4	33
58	Selumetinib in Children with Inoperable Plexiform Neurofibromas. <i>New England Journal of Medicine</i> , 2020, 382, 1430-1442.	27.0	360
59	A Systematic Review of Pediatric Phase I Trials in Oncology: Toxicity and Outcomes in the Era of Targeted Therapies. <i>Oncologist</i> , 2020, 25, 532-540.	3.7	15
60	Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	28
61	Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. <i>Lancet Oncology</i> , 2020, 21, 1099-1109.	10.7	59
62	Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 1527-1538.	1.6	58
63	Disease-free interval and tumor functional status can be used to select patients for resection/ablation of liver metastases from adrenocortical carcinoma: insights from a multi-institutional study. <i>Hpb</i> , 2020, 22, 169-175.	0.3	9
64	Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer. , 2020, 8, e000655.		41
65	CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1938-1950.	1.6	273
66	¹⁸ F-FDG PET Assessment of Malignant Pleural Mesothelioma: Total Lesion Volume and Total Lesion Glycolysis—The Central Role of Volume. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1570-1575.	5.0	4
67	Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 828-836.	7.0	35
68	Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 581801.	2.8	11
69	Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 2318-2326.	7.0	54
70	Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study. <i>Blood</i> , 2020, 136, 43-45.	1.4	10
71	Preliminary Results of a Response-Adapted Study of Ibrutinib and Isavuconazole with Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) for Secondary CNS Lymphoma. <i>Blood</i> , 2020, 136, 24-25.	1.4	7
72	Pre-CAR Blinatumomab Is Associated with Increased Post-CD19 CAR Relapse and Decreased Event Free Survival. <i>Blood</i> , 2020, 136, 13-14.	1.4	19

#	ARTICLE	IF	CITATIONS
73	Phase 1b/2 Study of Viper (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis. <i>Blood</i> , 2020, 136, 44-45.	1.4	13
74	A randomized, double-blind, phase II clinical trial of GI-6301 (yeast-brachyury vaccine) versus placebo in combination with standard of care definitive radiotherapy in locally advanced, unresectable, chordoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11527-11527.	1.6	8
75	A phase II trial of the DNA methyl transferase inhibitor, SGI-110 (Guadecitabine), in children and adults with SDH-deficient GIST, pheochromocytoma, and paraganglioma, and HLRCC-associated kidney cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11540-11540.	1.6	5
76	A phase I trial of pomalidomide in combination with liposomal doxorubicin in patients with Kaposi sarcoma with or without other KSHV-associated diseases.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11552-11552.	1.6	3
77	Ipilimumab challenge/re-challenge in metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors treated with cabozantinib+nivolumab (CaboNivo) or cabozantinib+nivolumab+ipilimumab (CaboNivolpi).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5039-5039.	1.6	2
78	Phase II study of olaparib in malignant mesothelioma (MM) to correlate efficacy with germline and somatic mutations in DNA repair genes.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9054-9054.	1.6	13
79	Phase II study of nivolumab (anti-PD1), tadalafil, and oral vancomycin in patients with refractory primary hepatocellular carcinoma or liver dominant metastatic cancer from colorectal or pancreatic cancers.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS4656-TPS4656.	1.6	3
80	A phase I/II study of Pexa-Vec oncolytic virus in combination with immune checkpoint inhibition in refractory colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 117-117.	1.6	8
81	Evaluating biomarkers in metastatic castration-resistant prostate cancer patients treated with enzalutamide: PSA, circulating tumor cell counts, AR-V7 status and radiographic progression.. <i>Journal of Clinical Oncology</i> , 2020, 38, e17569-e17569.	1.6	0
82	Phase I expansion study of cabozantinib plus nivolumab (CaboNivo) in metastatic urothelial carcinoma (mUC) patients (pts) with progressive disease following immune checkpoint inhibitor (ICI) therapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5037-5037.	1.6	2
83	Phase I/II study of T-DM1 alone versus T-DM1 and metronomic temozolomide in secondary prevention of HER2-positive breast cancer brain metastases following stereotactic radiosurgery.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS2572-TPS2572.	1.6	0
84	Randomized phase II trial of topotecan plus M6620 (VX-970) versus topotecan alone in patients with relapsed small-cell neuroendocrine cancers including small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS3653-TPS3653.	1.6	0
85	Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion with or without nab-paclitaxel.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3553-3553.	1.6	1
86	A Phase 1 Single Dose Escalation Study of Palifermin Administered Pre-Transplant Conditioning in Subjects Undergoing Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 21-21.	1.4	1
87	Tumor grade and sex should influence the utilization of portal lymphadenectomy for early stage intrahepatic cholangiocarcinoma. <i>Hpb</i> , 2019, 21, 419-424.	0.3	8
88	Impact of the 2014 NIH chronic graft-versus-host disease scoring criteria modifications assessed in a large cohort of severely affected patients. <i>Bone Marrow Transplantation</i> , 2019, 54, 76-84.	2.4	12
89	A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 247-257.	2.8	13
90	A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2019, 18, e349-e360.	2.3	31

#	ARTICLE	IF	CITATIONS
91	Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1447-1457.	1.1	136
92	A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor. <i>Clinical Cancer Research</i> , 2019, 25, 6302-6308.	7.0	13
93	Reproducibility of pharmacogenetics findings for paclitaxel in a heterogeneous population of patients with lung cancer. <i>PLoS ONE</i> , 2019, 14, e0212097.	2.5	6
94	Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 9008-9013.	7.1	108
95	Evaluation of confocal endoscopic microscopy for detection of early-stage gastric cancer in hereditary diffuse gastric cancer (HDGC) syndrome. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 407-411.	1.4	12
96	Survey of Surgical Oncology Fellowship Graduates 2005-2016: Insight into Initial Practice. <i>Annals of Surgical Oncology</i> , 2019, 26, 1622-1628.	1.5	16
97	Viral, immunologic, and clinical features of primary effusion lymphoma. <i>Blood</i> , 2019, 133, 1753-1761.	1.4	87
98	Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract Cancer. <i>Hepatology</i> , 2019, 69, 2048-2060.	7.3	77
99	Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant. <i>Blood</i> , 2019, 134, 1536-1536.	1.4	1
100	Phase 1b Study of Viper (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis. <i>Blood</i> , 2019, 134, 2867-2867.	1.4	4
101	Infectious Complications Associated with CAR T-Cell Therapy. <i>Blood</i> , 2019, 134, 4449-4449.	1.4	6
102	Preliminary results of a phase I clinical trial using an autologous dendritic cell cancer vaccine targeting HER2 in patients with metastatic cancer or operated high-risk bladder cancer (NCT01730118). <i>Journal of Clinical Oncology</i> , 2019, 37, 2639-2639.	1.6	5
103	Randomized phase II study of cladribine with simultaneous or delayed rituximab in patients with untreated hairy cell leukemia. <i>Journal of Clinical Oncology</i> , 2019, 37, 7003-7003.	1.6	5
104	Circulating tumor cell (CTC) enumeration in patients (pts) with metastatic genitourinary (mGU) tumors treated in a phase I study of cabozantinib and nivolumab (CaboNivo) +/- ipilimumab (CaboNivolpi). <i>Journal of Clinical Oncology</i> , 2019, 37, 4555-4555.	1.6	0
105	Prognostic value of sequential ¹⁸ F-FDG + Na ¹⁸ F PET/CT (NaF+FDG PET) in metastatic genitourinary (GU) cancer patients (pts) treated with cabozantinib/nivolumab +/- ipilimumab (CaboNivolpi). <i>Journal of Clinical Oncology</i> , 2019, 37, 4544-4544.	1.6	0
106	Response-Adapted Therapy in HIV-Associated Diffuse Large B-Cell Lymphoma: Updated Results of a Prospective Phase II Study of Short-Course-EPOCH-RR. <i>Blood</i> , 2019, 134, 4080-4080.	1.4	0
107	Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 207-215.	10.7	167
108	Volumetric MRI Analysis of Plexiform Neurofibromas in Neurofibromatosis Type 1. <i>Academic Radiology</i> , 2018, 25, 144-152.	2.5	17

#	ARTICLE	IF	CITATIONS
109	Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients. <i>Clinical Cancer Research</i> , 2018, 24, 2859-2872.	7.0	40
110	<i>MYC</i> gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R. <i>Leukemia and Lymphoma</i> , 2018, 59, 505-508.	1.3	13
111	Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib. <i>Clinical Cancer Research</i> , 2018, 24, 753-765.	7.0	26
112	Host-related immunodeficiency in the development of multiple myeloma. <i>Leukemia and Lymphoma</i> , 2018, 59, 1127-1132.	1.3	16
113	Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. , 2018, 6, 141.		214
114	Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 prospective, multicentre, single-arm phase 2 study. <i>Lancet Haematology</i> ,the, 2018, 5, e609-e617.	4.6	152
115	Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer. , 2018, 6, 91.		51
116	An Examination of Applicants and Factors Associated with Matriculation to Complex General Surgical Oncology Fellowship Training Programs. <i>Annals of Surgical Oncology</i> , 2018, 25, 3436-3442.	1.5	23
117	Metabolomic and BH3 profiling of esophageal cancers: novel assessment methods for precision therapy. <i>BMC Gastroenterology</i> , 2018, 18, 94.	2.0	6
118	A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer. <i>Journal of Translational Medicine</i> , 2018, 16, 196.	4.4	19
119	End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making. <i>Haematologica</i> , 2018, 103, 1337-1344.	3.5	63
120	Circulating Tumor DNA Dynamics during Therapy Predict Outcomes in Mantle Cell Lymphoma. <i>Blood</i> , 2018, 132, 147-147.	1.4	12
121	Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas. <i>Neuro-Oncology</i> , 2017, 19, now158.	1.2	41
122	A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 77-85.	1.9	40
123	Radiology Reports With Hyperlinks Improve Target Lesion Selection and Measurement Concordance in Cancer Trials. <i>American Journal of Roentgenology</i> , 2017, 208, W31-W37.	2.2	10
124	Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 4633-4641.	7.0	68
125	A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma. <i>Oncologist</i> , 2017, 22, 505-e49.	3.7	20
126	Clinical significance of IgE in a large cohort of patients with moderate or severe chronic graft-versus-host disease. <i>American Journal of Hematology</i> , 2017, 92, E162-E164.	4.1	3

#	ARTICLE	IF	CITATIONS
127	Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. <i>Cancer Cell</i> , 2017, 31, 833-843.e5.	16.8	383
128	Predictors for Permanent Discontinuation of Systemic Immunosuppression in Severely Affected Chronic Graft-Versus-Host Disease Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1980-1988.	2.0	6
129	SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma. <i>Surgery</i> , 2017, 161, 230-239.	1.9	60
130	Procalcitonin and cytokine profiles in engraftment syndrome in pediatric stem cell transplantation. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26273.	1.5	11
131	Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 66, 545-551.	3.7	624
132	Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-cell Leukemia/lymphoma. <i>Clinical Cancer Research</i> , 2017, 23, 35-42.	7.0	31
133	Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone. <i>Leukemia and Lymphoma</i> , 2017, 58, 639-645.	1.3	11
134	Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. <i>Blood Advances</i> , 2017, 1, 1911-1918.	5.2	37
135	Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer. , 2017, 5, 93.		56
136	Thymic epithelial tumors and metastasis to the brain: a case series and systematic review. <i>Translational Lung Cancer Research</i> , 2017, 6, 588-599.	2.8	7
137	Outcomes of children with hereditary medullary thyroid carcinoma (MTC) treated with vandetanib.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10540-10540.	1.6	2
138	A phase I study of cabozantinib plus nivolumab (CaboNivo) and cabonivo plus ipilimumab (CaboNivolpi) in patients (pts) with refractory metastatic (m) urothelial carcinoma (UC) and other genitourinary (GU) tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4562-4562.	1.6	16
139	Combination of PDL-1 and PARP inhibition in an unselected population with metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 5026-5026.	1.6	13
140	A pilot study of immune checkpoint inhibition in combination with radiation therapy in patients with metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15786-e15786.	1.6	8
141	Local ablative therapy (LAT) for oligoprogressive, EGFR-mutant, non-small cell lung cancer (NSCLC) after treatment with osimertinib.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20545-e20545.	1.6	4
142	A phase I study of cabozantinib plus nivolumab (CaboNivo) and ipilimumab (CaboNivolpi) in patients (pts) with refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 293-293.	1.6	14
143	Tremelimumab: A monoclonal antibody against CTLA-4 in combination with radiofrequency ablation (RFA) in patients with biliary tract carcinoma (BTC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 88-88.	1.6	0
144	A phase I dose expansion cohort study of dasatinib in combination with bevacizumab in advanced solid tumors (NCT01445509).. <i>Journal of Clinical Oncology</i> , 2017, 35, 2585-2585.	1.6	0

#	ARTICLE	IF	CITATIONS
145	Effects of <i>UGT1A1</i> genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 461-473.	2.0	32
146	Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma. <i>Haematologica</i> , 2016, 101, e27-e29.	3.5	24
147	Characterization and Risk Factor Analysis of Osteoporosis in a Large Cohort of Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1517-1524.	2.0	16
148	Expression of mesothelin in thymic carcinoma and its potential therapeutic significance. <i>Lung Cancer</i> , 2016, 101, 104-110.	2.0	18
149	Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 4125-4131.	1.6	91
150	Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1993-2005.	1.1	96
151	Identification of novel SNPs associated with risk and prognosis in patients with castration-resistant prostate cancer. <i>Pharmacogenomics</i> , 2016, 17, 1979-1986.	1.3	6
152	Thoracic Surgery in Chronic Granulomatous Disease: a 25-Year Single-Institution Experience. <i>Journal of Clinical Immunology</i> , 2016, 36, 677-683.	3.8	5
153	<i>EGFR</i> Mutations in Latinos From the United States and Latin America. <i>Journal of Global Oncology</i> , 2016, 2, 259-267.	0.5	15
154	Female fertility following dose-adjusted EPOCH-R chemotherapy in primary mediastinal B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2016, 57, 1616-1624.	1.3	15
155	Significance of preoperative radiographic pancreatic density in predicting pancreatic fistula after surgery for pancreatic neuroendocrine tumors. <i>American Journal of Surgery</i> , 2016, 212, 40-46.	1.8	4
156	The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 235-251.	2.5	18
157	Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas. <i>Clinical Cancer Research</i> , 2016, 22, 3182-3191.	7.0	109
158	Clinical Features and Outcomes of Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-associated Inflammation: Prospective Characterization of KSHV Inflammatory Cytokine Syndrome (KICS). <i>Clinical Infectious Diseases</i> , 2016, 62, 730-738.	5.8	135
159	Resection of primary tumor site is associated with prolonged survival in metastatic nonfunctioning pancreatic neuroendocrine tumors. <i>Surgery</i> , 2016, 159, 311-319.	1.9	91
160	Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity. <i>Clinical Cancer Research</i> , 2016, 22, 310-318.	7.0	48
161	A phase II trial of vandetanib (ZD6474) in children and adults with wild-type gastrointestinal stromal tumors. <i>Journal of Clinical Oncology</i> , 2016, 34, 11009-11009.	1.6	3
162	SARCO16: Phase II study of everolimus in combination with bevacizumab in sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST). <i>Journal of Clinical Oncology</i> , 2016, 34, 11053-11053.	1.6	19

#	ARTICLE	IF	CITATIONS
163	Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial. <i>Oncotarget</i> , 2016, 7, 69014-69023.	1.8	38
164	ATM deficiency promotes development of murine B-cell lymphomas that resemble diffuse large B-cell lymphoma in humans. <i>Blood</i> , 2015, 126, 2291-2301.	1.4	13
165	Predictive models for ocular chronic graft-versus-host disease diagnosis and disease activity in transplant clinical practice. <i>Haematologica</i> , 2015, 100, 1228-1236.	3.5	21
166	Risk Factors and Characterization of Vitiligo and Alopecia Areata in Patients With Chronic Graft-vs-Host Disease. <i>JAMA Dermatology</i> , 2015, 151, 23.	4.1	31
167	Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial. <i>BMJ Open</i> , 2015, 5, e008248-e008248.	1.9	29
168	Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. <i>JAMA Oncology</i> , 2015, 1, 746.	7.1	266
169	Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2015, 1, 1087.	7.1	80
170	Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 177-186.	10.7	240
171	Imatinib Mesylate for the Treatment of Steroid-Refractory Sclerotic-Type Cutaneous Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1083-1090.	2.0	53
172	High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses. <i>Clinical Cancer Research</i> , 2015, 21, 4312-4320.	7.0	9
173	EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment. <i>Blood</i> , 2015, 126, 863-872.	1.4	235
174	Long-Term Outcome of Bilateral Laparoscopic Adrenalectomy Measured by Disease-Specific Questionnaire in a Unique Group of Patients with Cushing's Syndrome. <i>Annals of Surgical Oncology</i> , 2015, 22, 699-706.	1.5	13
175	Viable tumor volume: Volume of interest within segmented metastatic lesions, a pilot study of proposed computed tomography response criteria for urothelial cancer. <i>European Journal of Radiology</i> , 2015, 84, 1708-1714.	2.6	9
176	¹⁸ F-fluorodeoxyglucose Positron Emission Tomography in Kaposi Sarcoma Herpesvirus-Associated Multicentric Castlemans Disease: Correlation With Activity, Severity, Inflammatory and Virologic Parameters. <i>Journal of Infectious Diseases</i> , 2015, 212, 1250-1260.	4.0	32
177	Impact of telomere length on survival in classic and variant hairy cell leukemia. <i>Leukemia Research</i> , 2015, 39, 1360-1366.	0.8	8
178	The impact of leukapheresis on immune-cell number and function in patients with advanced cancer. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1429-1435.	4.2	2
179	Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decades. <i>Hepatic Oncology</i> , 2015, 2, 39-50.	4.2	10
180	Efficacy of Intralesional Botulinum Toxin A for Treatment of Painful Cutaneous Leiomyomas. <i>JAMA Dermatology</i> , 2015, 151, 1096.	4.1	15

#	ARTICLE	IF	CITATIONS
181	T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. <i>Lancet, The</i> , 2015, 385, 517-528.	13.7	2,476
182	Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R. <i>Blood</i> , 2015, 126, 342-342.	1.4	14
183	Alemtuzumab-Cyclosporine Versus Tacrolimus-Methotrexate-Sirolimus for Graft-Versus-Host Disease Prophylaxis in Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Donors: Final Results of a Randomized Trial. <i>Blood</i> , 2015, 126, 65-65.	1.4	2
184	The outcome of ALK positive and ALK negative anaplastic large cell lymphoma (ALCL) following DA-EPOCH.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8564-8564.	1.6	1
185	Cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 235-235.	1.6	1
186	High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis. <i>Oncotarget</i> , 2015, 6, 11694-11703.	1.8	66
187	EGFR mutations in Latinos from the United States and Latin America.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8070-8070.	1.6	0
188	Clinical and Immunologic Characteristics of Patients with Chronic Graft-Versus-Host Disease Persisting Seven or More Years after Diagnosis. <i>Blood</i> , 2015, 126, 1937-1937.	1.4	0
189	A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study. <i>Clinical Cancer Research</i> , 2014, 20, 5392-5402.	7.0	83
190	Factors Predictive of Relapse of Acute Leukemia in Children after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1033-1039.	2.0	17
191	Profound Prevention of Experimental Brain Metastases of Breast Cancer by Temozolomide in an MGMT-Dependent Manner. <i>Clinical Cancer Research</i> , 2014, 20, 2727-2739.	7.0	57
192	Puberty and Plexiform Neurofibroma Tumor Growth in Patients with Neurofibromatosis Type I. <i>Journal of Pediatrics</i> , 2014, 164, 620-624.	1.8	28
193	Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2014, 15, 191-200.	10.7	111
194	Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States11Funding source: The US Office of Management and Budget (0925-0046).. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 637-644.	1.6	46
195	Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease. <i>Blood</i> , 2014, 124, 3544-3552.	1.4	92
196	Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4501-4501.	1.6	28
197	A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors. <i>Oncotarget</i> , 2014, 5, 8161-8172.	1.8	31
198	Systemic chemotherapy for the treatment of advanced biliary tract carcinoma (BTC).. <i>Journal of Clinical Oncology</i> , 2014, 32, e15129-e15129.	1.6	0

#	ARTICLE	IF	CITATIONS
199	A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety. <i>Molecular and Clinical Oncology</i> , 2013, 1, 565-569.	1.0	26
200	Clinical and Correlative Pilot Study Of Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Extended Dosing (CRd + R) In High Risk Smoldering Multiple Myeloma Patients. <i>Blood</i> , 2013, 122, 1939-1939.	1.4	6
201	Concurrent Expression Of MYC/BCL2 Protein In Newly Diagnosed DLBCL Is Not Associated With An Inferior Survival Following EPOCH-R Therapy. <i>Blood</i> , 2013, 122, 3029-3029.	1.4	8
202	Phase II Clinical and Correlative Study Of Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Extended Dosing (CRD-R) Induces High Rates Of MRD Negativity In Newly Diagnosed Multiple Myeloma (MM) Patients. <i>Blood</i> , 2013, 122, 538-538.	1.4	30
203	Serum Heavy-Light Chains (HLC) and Free Light Chains (FLC) As Predictors For Early CR In Newly Diagnosed Myeloma Patients Treated With Carfilzomib, Lenalidomide, and Dexamethasone (CRd). <i>Blood</i> , 2013, 122, 762-762.	1.4	3
204	SARC006: Phase II trial of chemotherapy in sporadic and neurofibromatosis type 1 (NF1)-associated high-grade malignant peripheral nerve sheath tumors (MPNSTs).. <i>Journal of Clinical Oncology</i> , 2013, 31, 10522-10522.	1.6	19
205	Phase I and pharmacokinetic study of sorafenib in Kaposi sarcoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10588-10588.	1.6	2
206	CUSTOM (Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small) Tj ETQq0 0 0 rgBT /Overlock 10 Tf of mass customization and product postponement.. <i>Journal of Clinical Oncology</i> , 2013, 31, 6524-6524.	1.6	2
207	Two parallel randomized phase II studies of selumetinib (S) and erlotinib (E) in advanced non-small cell lung cancer selected by KRAS mutations.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8026-8026.	1.6	17
208	A phase II study of cabozantinib (XL184) in patients with advanced/metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS4589-TPS4589.	1.6	3
209	A phase II randomized clinical trial of samarium-153 EDTMP (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration-resistant prostate cancer (mCRPC) after docetaxel.. <i>Journal of Clinical Oncology</i> , 2013, 31, 102-102.	1.6	14
210	Effect of the addition of platinum to gemcitabine on outcome in patients with advanced pancreatic cancer who progress on gemcitabine: A comprehensive analysis of published trials.. <i>Journal of Clinical Oncology</i> , 2013, 31, 275-275.	1.6	0
211	Phase I/II study of the safety, pharmacokinetics, and efficacy of pomalidomide in the treatment of Kaposi sarcoma in individuals with or without HIV.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS10595-TPS10595.	1.6	0
212	Biologic variations of plasma cells in the bone marrow of smoldering multiple myeloma (SMM) and multiple myeloma (MM) patients: Multiple biopsies in the same patient.. <i>Journal of Clinical Oncology</i> , 2013, 31, e19506-e19506.	1.6	0
213	Chronic Graft-Versus-Host Disease (cGVHD) Patients with Bronchiolitis Obliterans Syndrome (BOS) Have Worse Clinical Manifestations and Severity of cGVHD with More Impairment in Self-Assessed Physical and Mental Health than cGVHD Patients without BOS. <i>Blood</i> , 2012, 120, 1939-1939.	1.4	2
214	Influence of Graft Versus-Host Disease Prophylaxis Regimen On T-Cell Repertoire Diversity Following Reduced-Intensity HLA-Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2012, 120, 3054-3054.	1.4	1
215	Bortezomib + DA-EPOCH-R Induction Therapy Followed by Maintenance Bortezomib Versus Observation in Newly Diagnosed Mantle Cell Lymphoma. <i>Blood</i> , 2012, 120, 3672-3672.	1.4	7
216	A Phase II Trial of Alemtuzumab (Campath) with DA-EPOCH-R in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma. <i>Blood</i> , 2012, 120, 3709-3709.	1.4	1

#	ARTICLE	IF	CITATIONS
217	Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone (CRd) in Newly Diagnosed Multiple Myeloma (MM) Patients. <i>Blood</i> , 2012, 120, 732-732.	1.4	7
218	Association of idiotype vaccine-induced T-cell response with improved survival and time-to-next treatment (TTNT) in untreated mantle cell lymphoma (MCL).. <i>Journal of Clinical Oncology</i> , 2012, 30, 2528-2528.	1.6	2
219	Dual antiangiogenic therapy using lenalidomide and bevacizumab with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4569-4569.	1.6	3
220	Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone (CRd) in newly diagnosed multiple myeloma (MM) patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, e18568-e18568.	1.6	4
221	A phase I study of TRC105 (anti-CD105 [endoglin] antibody) in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 117-117.	1.6	2
222	Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 207-207.	1.6	5
223	Vaccine therapy with tumor-specific mutated ras peptides and IL-2, GM-CSF, or both in adult patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2577-2577.	1.6	0
224	A phase I study of TRC105 (Anti-CD105 [endoglin] antibody) in metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 3043-3043.	1.6	3
225	Efficacy of alemtuzumab (ALZ) in combination with dose-adjusted EPOCH (DA-EPOCH) in untreated nodal peripheral T-cell lymphoma (PTCL).. <i>Journal of Clinical Oncology</i> , 2012, 30, 8051-8051.	1.6	0
226	Clinical, Immunologic, and Virologic Findings in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Lymphomas Suggest KSHV-Associated Inflammatory Syndromes Contribute to Symptoms and Disease Pathogenesis.. <i>Blood</i> , 2012, 120, 2708-2708.	1.4	8
227	Factors Predictive of Relapse of Hematologic Malignancies in Pediatric Patients Post Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2012, 120, 4206-4206.	1.4	0
228	Pre-Emptive T-Rapa Cell DLI for Therapy of High-Risk Lymphoma After Low-Intensity Allogeneic HCT. <i>Blood</i> , 2012, 120, 471-471.	1.4	0
229	Minor Histocompatibility Antigen Mismatch and Incidence of Graft Versus Host Disease, Event-Free, and Overall Survival in Patients Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2012, 120, 4201-4201.	1.4	0
230	Concurrent Fludarabine and Cyclophosphamide As a Reduced Intensity Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation Ablates Host T-Cells and Results in Rapid Full Donor Chimerism. <i>Blood</i> , 2011, 118, 1937-1937.	1.4	0
231	An Interleukin-6-Related Systemic Inflammatory Syndrome in Patients Co-Infected with Kaposi Sarcoma-Associated Herpesvirus and HIV but without Multicentric Castleman Disease. <i>Clinical Infectious Diseases</i> , 2010, 51, 350-358.	5.8	266
232	Pilot Randomized Trial Comparing the Effects of Alemtuzumab and Cyclosporine Versus Tacrolimus, Methotrexate and Sirolimus on Graft Versus Host Disease Prevention, Engraftment and Immune Reconstitution After Reduced Intensity Unrelated Donor Transplantation.. <i>Blood</i> , 2010, 116, 1245-1245.	1.4	2
233	Use of Targeted Lymphocyte Depletion as a Personalized Approach to Improve Engraftment and Disease Control Following Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-Matched Unrelated Donors. <i>Blood</i> , 2010, 116, 3530-3530.	1.4	0
234	Alemtuzumab (Campath 1-H) in Patients with HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma.. <i>Blood</i> , 2008, 112, 2010-2010.	1.4	1

#	ARTICLE	IF	CITATIONS
235	Soluble BAFF Is Elevated Following Allogeneic SCT but Is Not an Early Predictor for the Development of cGVHD.. Blood, 2007, 110, 167-167.	1.4	1
236	Early Results of a Clinical Trial Using Targeted Oncolytic Virotherapy in Kaposi Sarcoma Herpes Virus (KSHV) Associated Multicentric Castleman's Disease (MCD).. Blood, 2007, 110, 514-514.	1.4	1
237	Elevated Serum Interleukin-7 Levels Precede the Development of Acute Graft-Versus-Host Disease.. Blood, 2007, 110, 1064-1064.	1.4	8
238	Ex-Vivo Reduction of Allograft T Cell Dose Does Not Prevent Acute Graft-vs-Host Disease after Reduced-Intensity Hematopoietic Stem Cell Transplantation.. Blood, 2006, 108, 2871-2871.	1.4	0
239	Early selection in a randomized phase II clinical trial. Statistics in Medicine, 2002, 21, 1711-1726.	1.6	42
240	A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma. Cancer, 2002, 94, 2333-2343.	4.1	1
241	Clinical Trial Designs for the Early Clinical Development of Therapeutic Cancer Vaccines. Journal of Clinical Oncology, 2001, 19, 1848-1854.	1.6	113
242	Phase I Clinical Trial of Oral COL-3, a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer. Journal of Clinical Oncology, 2001, 19, 584-592.	1.6	142
243	Factors Associated With Response to High-Dose Interleukin-2 in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 2001, 19, 3477-3482.	1.6	289
244	Factors Affecting Survival After Complete Response to Isolated Limb Perfusion in Patients With In-Transit Melanoma. Annals of Surgical Oncology, 2001, 8, 771-778.	1.5	37
245	Polymorphisms in inflammatory cytokines and Fcγ3 receptors in childhood chronic immune thrombocytopenic purpura: a pilot study. British Journal of Haematology, 2001, 113, 596-599.	2.5	87
246	Biomarker Assays in Nipple Aspirate Fluid. Breast Journal, 2001, 7, 378-387.	1.0	38
247	Melanoma antigen expression in serial fine-needle aspiration samples in patients with metastatic malignant melanoma participating in immunotherapy clinical trials. Cancer, 2001, 93, 409-414.	4.1	10
248	Comparison of antibodies to MART-1 and MelanA in fine-needle aspiration samples of metastatic malignant melanoma. Diagnostic Cytopathology, 2001, 25, 78-79.	1.0	10
249	Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes. , 2000, 86, 818-826.		52
250	The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines. Cancer Immunology, Immunotherapy, 2000, 49, 517-529.	4.2	73
251	Activity of Thalidomide in AIDS-Related Kaposi's Sarcoma. Journal of Clinical Oncology, 2000, 18, 2593-2602.	1.6	288
252	Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes. International Journal of Cancer, 2000, 86, 818-826.	5.1	3

#	ARTICLE	IF	CITATIONS
253	Prospective Randomized Trial of the Treatment of Patients With Metastatic Melanoma Using Chemotherapy With Cisplatin, Dacarbazine, and Tamoxifen Alone or in Combination With Interleukin-2 and Interferon Alfa-2b. <i>Journal of Clinical Oncology</i> , 1999, 17, 968-968.	1.6	307
254	Pharmacokinetics and relative bioavailability of carboxyamido-triazole with respect to food and time of administration: use of a single model for simultaneous determination of changing parameters. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1998, 26, 673-687.	0.6	7
255	Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer. <i>Cancer</i> , 1998, 83, 1980-1988.	4.1	16
256	Bronchiolization of the alveoli in lung cancer: Pathology, patterns of differentiation and oncogene expression. , 1998, 75, 489-496.		29
257	Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. , 1998, 75, 517-524.		160
258	Response during radiotherapy may be associated with outcome in mediastinal Hodgkin's disease. <i>Radiation Oncology Investigations</i> , 1998, 6, 216-225.	0.9	3
259	Selection of local therapy after neoadjuvant chemotherapy in patients with stage IIIA,B breast cancer. <i>Annals of Surgical Oncology</i> , 1998, 5, 150-158.	1.5	39
260	A Phase I/II Study of the Protease Inhibitor Ritonavir in Children With Human Immunodeficiency Virus Infection. <i>Pediatrics</i> , 1998, 101, 335-343.	2.1	101
261	Effect of L-Carnitine on Human Immunodeficiency Virus-1 Infection-Associated Apoptosis: A Pilot Study. <i>Blood</i> , 1998, 91, 3817-3824.	1.4	63
262	A Phase I/II Study of the Protease Inhibitor Indinavir in Children With HIV Infection. <i>Pediatrics</i> , 1998, 102, 101-109.	2.1	76
263	Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer. <i>Cancer</i> , 1998, 83, 1980-1988.	4.1	2
264	Simian virus-40 large-T antigen binds p53 in human mesotheliomas. <i>Nature Medicine</i> , 1997, 3, 908-912.	30.7	244
265	Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. <i>Annals of Surgical Oncology</i> , 1997, 4, 628-633.	1.5	191
266	Surgically debulked malignant pleural mesothelioma: Results and prognostic factors. <i>Annals of Surgical Oncology</i> , 1997, 4, 215-222.	1.5	155
267	Parental Expressed Needs. <i>Journal of HIV/AIDS Prevention and Education for Adolescents and Children</i> , 1996, 1, 35-52.	0.1	4
268	MYC family DNA amplification in 126 tumor cell lines from patients with small cell lung cancer. <i>Journal of Cellular Biochemistry</i> , 1996, 63, 210-217.	2.6	65
269	Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors. , 1996, 78, 901-911.		112
270	Lack of Correlation Between Prostate-Specific Antigen and the Presence of Measurable Soft Tissue Metastases in Hormone-Refractory Prostate Cancer. <i>Cancer Investigation</i> , 1996, 14, 513-517.	1.3	45

#	ARTICLE	IF	CITATIONS
271	Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors. <i>Cancer</i> , 1996, 78, 901-911.	4.1	77
272	Expansion of the Ki-67 proliferative compartment correlates with degree of Dysplasia in Barrett's esophagus. <i>Cancer</i> , 1995, 75, 423-429.	4.1	166
273	Human Immunodeficiency Virus Type 1 (HIV-1) Viremia Changes and Development of Drug-Related Mutations in Patients with Symptomatic HIV-1 Infection Receiving Alternating or Simultaneous Zidovudine and Didanosine Therapy. <i>Journal of Infectious Diseases</i> , 1995, 171, 1152-1158.	4.0	47
274	A pilot study of amiodarone with infusional doxorubicin or vinblastine in refractory breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 35, 457-463.	2.3	25
275	Localization of ¹¹¹ Indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. <i>Cancer</i> , 1994, 73, 1731-1737.	4.1	204
276	Clara cell 10 kDa protein mRNA in normal and atypical regions of human respiratory epithelium. <i>International Journal of Cancer</i> , 1994, 58, 629-637.	5.1	32
277	Localization of ¹¹¹ Indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. , 1994, 73, 1731.		1
278	A phase II evaluation of thiotepa in pediatric central nervous system malignancies. <i>Cancer</i> , 1993, 72, 271-275.	4.1	60
279	Prognostic implications of a bone marrow histopathologic classification system in mycosis fungoides and the SÃ©zary syndrome. <i>Cancer</i> , 1993, 72, 726-734.	4.1	32
280	Flow cytometric DNA analysis of interleukin-2 responsive renal cell carcinoma. <i>Journal of Surgical Oncology</i> , 1993, 53, 252-255.	1.7	4
281	Correlative Detection of Human Immunodeficiency Virus (HIV) Antigen p24 and Epsteinâ€Barr Virus DNA <i>In Vitro</i>: Clinical Influence on HIV Infection. <i>Microbiology and Immunology</i> , 1992, 36, 905-909.	1.4	1
282	Analysis of iodine-125 interstitial therapy in the treatment of localized carcinoma of the prostate. <i>Journal of Surgical Oncology</i> , 1991, 46, 235-240.	1.7	4
283	Determinants of survival in patients with unresectable colorectal liver metastases. <i>Journal of Surgical Oncology</i> , 1989, 40, 245-251.	1.7	36
284	Extremity soft tissue sarcomas: Analysis of prognostic variables in 300 cases and evaluation of tumor necrosis as a factor in stratifying higher-grade sarcomas. <i>Journal of Surgical Oncology</i> , 1989, 41, 263-273.	1.7	61
285	Computerized tomographic prediction of extraluminal spread and prognostic implications of lesion width in esophageal carcinoma. <i>Cancer</i> , 1988, 62, 1287-1292.	4.1	30
286	Low rate of subsequent malignant neoplasms following CAR T-cell therapy. <i>Blood Advances</i> , 0, , .	5.2	8